Article citationsMore>>

Williams, H.C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T.R., Schmidt, E., Chalmers, J.R., Childs, M., Walton, S., Harman, K., Chapman, A., Whitham, D., Nunn, A.J., UK Dermatology Clinical Trials Network BLISTER Study Group (2017) Doxycycline versus Prednisolone as an Initial Treatment Strategy for Bullous Pemphigoid: A Pragmatic, Non-Inferiority, Randomised Controlled Trial. Lancet (London, England), 389, 1630-1638.
https://doi.org/10.1016/S0140-6736(17)30560-3

has been cited by the following article:

• TITLE: Bullous Pemphigoid Induced by Doxycycline: Case Report and Literature Review

  AUTHORS: Mishal Al Mebayadh, Rahaf Aldawish, Sohail A. Butt, Abdulrahman Saad Aljahhan

  KEYWORDS: Bullous Pemphigoid, Doxycycline, Drug-Associated Bullous Pemphigoid

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.13 No.5, May 28, 2024

  ABSTRACT: Bullous pemphigoid (BP) is the most prevalent autoimmune sub-epidermal blistering disease that affects mainly the elderly and could lead to serious morbidity. It has numerous risk factors and triggers, including an aging population with several comorbidities and drug exposure. In the published paper, we reported a case about a 32 years old male patient with unknown medical conditions who presented with erythematous patches and plaques on the scalp, face, and trunk with scattered blisters two weeks after initiating doxycycline treatment for folliculitis. The exact pathogenesis of the drug-reaction in drug- associated bullous pemphigoid (DABP) remains controversial. In conclusion, it is crucial for clinicians to be aware of DABP when prescribing doxycycline. The purpose of this case report is to raise awareness of the possible association between bullous pemphigoid and doxycycline.